Navigation Links
NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
Date:10/6/2008

rially from those expressed or implied by the forward-looking statements, including adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statement. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
2. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
3. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
4. Pharmaleads Lead Candidate for Pain, PL37, Enters Phase I
5. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
10. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender offer ...   As a result of the waiver, the transaction ... complete the tender offer on January 24, 2014 following the currently ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... will be presented at the American College of,Cardiology's ... 2007 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. announced today that ... study of ranolazine shows there was no,adverse trend ... study did not meet the primary efficacy endpoint. ...
... in Intestinal Adenomas Suggesting,Possible Beneficial Mediation in the ... 07, 2007 /PRNewswire/ -- NutraCea,announced today the results ... bran,on the number of intestinal adenomas in cancerous ... of the prestigious British,Journal of Cancer conducted at ...
Cached Medicine Technology:CV Therapeutics Announces Topline MERLIN TIMI-36 Results 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 2British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 4
(Date:4/23/2014)... Effects of Midlife Occupational and Leisure Time Physical Activity ... physical activity in midlife increases the risk of mobility ... the risk. This is found in a study which ... The study was conducted at the Gerontology Research Center ... , Heavy physical labor is often repetitive, wears the ...
(Date:4/23/2014)... disease has been a rapidly evolving pursuit with ... crook in the research road, scientists have found ... associated with the disease. The report, which appears ... could have important implications for developing novel treatments. ... explain that for years, research has suggested a ...
(Date:4/22/2014)... decades researchers have characterized a set of clock genes ... all types of species, from flies to humans. Over ... surmise there are more. A team from the Perelman ... if big-data approaches could find them. , To ... PhD, professor of Pharmacology and first author Ron Anafi, ...
(Date:4/22/2014)... The risk of pregnancy among women using a ... more than 10 times greater over a 10-year period ... study by researchers at Yale University and UC Davis ... medical journal Contraception , the study found the ... marketed under the brand name Essure. , "This ...
(Date:4/22/2014)... NY, April 22, 2014Hemoglobin A1c is the standard measurement ... diabetes. Blood levels of A1c are typically measured every ... developed a data-based model that accurately estimates A1c using ... Diabetes Technology & Therapeutics ( DTT ), a ... article is available free on the DTT ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... Janssen-Cilag,EMEA, a division of Janssen Pharmaceutica ... received marketing authorisation in Finland and,Sweden for ... in men 18-64,years of age. These approvals ... authorisation procedure in seven European Union countries: ...
... Varian, Inc.,(NasdaqGS: VARI) today reported that its Board of ... Executive Officer, as Chairman,of the Board. He replaces Allen ... director term at the annual meeting of stockholders held on,February ... Executive,Officer. , "We were very fortunate ...
... in 3 will do so for Fido, if not for ... who won,t kick the habit for their own health will ... "We wanted to determine whether pet owners who learned that ... behavior," said Sharon Milberger, an epidemiologist at the Henry Ford ...
... frail for open-heart surgery CHICAGO, Feb 9 ... of his heart valve -- hardening that is formally ... out of the question. He,d already survived quadruple ... a century, Lafferty wasn,t a good candidate for heart ...
... LCA-Vision Full Value,Committee announced today that it has ... solicitation materials and is commencing,distribution of those soliciting ... LCAV ) ("LCAV") to solicit consents to replace ... five highly qualified nominees. The Full,Value Committee,s ...
... Nationwide tour to impact the lives of one million ... economic timesPLEASANTON, Calif., Feb. 9 Shaklee Corporation Chairman ... to promote an opportunity that offers economic support to ... to New York City, NY on Feb. 10."Families are ...
Cached Medicine News:Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 2Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 3Health News:Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 4Health News:Garry W. Rogerson Elected Chairman of the Board of Varian, Inc. 2Health News:Smokers Will Stop for Their Pet's Sake 2Health News:Diseased Heart Valve Replaced Through Small Chest Incision 2Health News:Diseased Heart Valve Replaced Through Small Chest Incision 3Health News:Diseased Heart Valve Replaced Through Small Chest Incision 4Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 2Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 3Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 4Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 5Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 6Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 7Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 8Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 9Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 10Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 11Health News:The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders 12Health News:Shaklee Hits the Road with its Infinite Possibilities Tour in New York, NY 2
... digital x-ray detectors from KUBTEC represents a ... 12 to 16 bit digital interface. The ... array sensor with pixel spacing down to ... low x-ray energies (10-50 kV) and an ...
... a breakthrough in specimen radiography. The XPERT represents ... 65,536 shades of gray in every digital x-ray ... changes in density that heretofore were lost to ... from 2 x 2 to 8 x 8 ...
The Triage Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment...
... in the field of Urodynamics, Albyn Medical recognised ... new chair is manufactured from the highest quality ... can be improved considerably if the patient is ... this aspect was given a high priority in ...
Medicine Products: